Aspirin for Preeclampsia Prevention: Dosing, Timing & Who Needs It
TL;DR
- Low-dose aspirin (81–162 mg daily) reduces preeclampsia risk by approximately 15–25% in high-risk pregnancies when started at 12–16 weeks of gestation.
- The USPSTF, ACOG, and SMFM all recommend aspirin for pregnant individuals with one or more high-risk factors or two or more moderate-risk factors.
- Bedtime dosing may improve efficacy based on the ASPRE trial findings.
- Aspirin is generally discontinued at 36 weeks unless a clinician advises otherwise.
- Screening for risk factors should occur at the first prenatal visit.
What Is Preeclampsia and Why Does Prevention Matter?
Preeclampsia is a hypertensive disorder of pregnancy characterized by new-onset hypertension (systolic blood pressure ≥ 140 mmHg or diastolic ≥ 90 mmHg) after 20 weeks of gestation, typically accompanied by proteinuria or end-organ dysfunction. It complicates an estimated 2–8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality.
The pathophysiology centers on abnormal placentation. In early pregnancy, trophoblast invasion of the spiral arteries is incomplete, leading to poor placental perfusion, endothelial dysfunction, and a systemic inflammatory response. This understanding is precisely why the aspirin preeclampsia prevention dose strategy works — aspirin inhibits cyclooxygenase-mediated thromboxane A₂ production, shifting the prostacyclin-to-thromboxane ratio in favor of vasodilation and reduced platelet aggregation, thereby improving placental blood flow during the critical window of spiral artery remodeling.
Preeclampsia cannot be cured except by delivery. Prevention, therefore, focuses on identifying at-risk individuals early and intervening before the pathologic cascade becomes irreversible. Among all pharmacologic strategies studied — including calcium supplementation, heparin, and antioxidants — low-dose aspirin in pregnancy remains the only intervention with robust evidence of benefit endorsed by major guideline bodies.
Who Should Take Aspirin? USPSTF and ACOG Risk-Factor Screening
Not every pregnant individual needs aspirin. Guidelines from the U.S. Preventive Services Task Force (USPSTF, 2021), the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal-Fetal Medicine (SMFM) use a structured risk-factor approach to identify candidates.
Risk-Factor Classification
| Category | Risk Factors | Aspirin Recommended If… |
|---|---|---|
| High-risk | History of preeclampsia (especially early-onset or severe); multifetal gestation (twins, triplets); chronic hypertension; pregestational diabetes (type 1 or 2); renal disease; autoimmune disease (SLE, antiphospholipid syndrome) | ≥ 1 high-risk factor is present |
| Moderate-risk | Nulliparity; obesity (BMI > 30 kg/m²); family history of preeclampsia (mother or sister); age ≥ 35 years; previous adverse pregnancy outcome (growth restriction, stillbirth, placental abruption); sociodemographic factors (Black race, low socioeconomic status); IVF conception; interpregnancy interval > 10 years | ≥ 2 moderate-risk factors are present |
| Low-risk | None of the above | Aspirin is not routinely recommended |
Key clinical point: The USPSTF 2021 recommendation statement (Grade B) advises using low-dose aspirin (81 mg/day) after 12 weeks of gestation in persons at high risk for preeclampsia. ACOG and SMFM concur, with ACOG's Practice Advisory reaffirming these criteria.
Screening in Practice
Risk-factor screening should occur at the first prenatal visit, ideally before 16 weeks of gestation. This is a clinical assessment — no specialized laboratory test or ultrasound is required at this stage, though some centers incorporate first-trimester uterine artery Doppler and biomarkers (PAPP-A, PlGF) as part of a multivariate predictive algorithm, as used in the ASPRE trial.
Clinicians should specifically ask about:
- Prior pregnancy complications, including gestational hypertension
- Medical comorbidities (hypertension, diabetes, lupus, kidney disease)
- Family history of preeclampsia
- Current pregnancy characteristics (multifetal, IVF)
The Evidence: Key Trials and Meta-Analyses
ASPRE Trial (2017)
The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) trial is the landmark study in this field. Published in the New England Journal of Medicine, this multicenter, double-blind, placebo-controlled trial randomized 1,776 women identified as high-risk by a first-trimester screening algorithm to receive either aspirin 150 mg nightly or placebo from 11–14 weeks through 36 weeks.
Results were striking: aspirin reduced the rate of preterm preeclampsia (delivery before 37 weeks) by 62% (odds ratio 0.38; 95% CI 0.20–0.74). The effect on term preeclampsia was not statistically significant, reinforcing the concept that early initiation — before 16 weeks — is critical for meaningful prevention.
Cochrane Systematic Review
The Cochrane review by Duley et al. (2019), encompassing over 60 trials and more than 37,000 women, concluded that antiplatelet agents (predominantly low-dose aspirin) reduced the risk of preeclampsia by approximately 17% (RR 0.83; 95% CI 0.77–0.89) and preterm birth by 9%. The benefit was consistent across subgroups.
PARIS Individual Patient Data Meta-Analysis
The Perinatal Antiplatelet Review of International Studies (PARIS) collaboration, published in The Lancet (2007), pooled individual patient data from 31 trials (over 32,000 women). Aspirin started at or before 16 weeks showed a larger reduction in preeclampsia risk than aspirin started later, and doses ≥ 75 mg appeared more effective than lower doses.
USPSTF Evidence Review (2021)
Henderson et al. conducted the systematic evidence review underpinning the USPSTF 2021 recommendation. Across 23 trials (over 29,000 participants), low-dose aspirin reduced preeclampsia risk by 15% (RR 0.85; 95% CI 0.75–0.95), with greater benefit observed when aspirin was started before 16 weeks and at doses of 100 mg or higher.
Aspirin 81 vs 150 mg for Preeclampsia: Dose Selection
One of the most debated questions in perinatal pharmacotherapy is whether 81 mg or 150 mg of aspirin is optimal. The answer depends partly on geography and partly on the evidence one prioritizes.
Dose Comparison Table
| Parameter | 81 mg (standard US dose) | 150 mg (ASPRE trial dose) |
|---|---|---|
| Guideline endorsement | USPSTF, ACOG, SMFM | FIGO, NICE (recommends 75–150 mg) |
| Key supporting evidence | Multiple trials, PARIS meta-analysis | ASPRE trial |
| Preterm preeclampsia reduction | ~15–25% (pooled) | ~62% (ASPRE) |
| Availability | OTC in US (standard baby aspirin) | Standard in many European countries; requires splitting or importing in the US |
| Safety profile | Well-established; minimal bleeding risk | Similar safety in ASPRE; slightly less long-term data |
| Practical considerations | Single tablet, widely available | May require two 75 mg tablets or one 150 mg tablet (less common in US pharmacies) |
ACOG's position: ACOG recommends 81 mg daily, acknowledging that higher doses (up to 162 mg, i.e., two 81-mg tablets) may be considered based on clinical judgment, particularly in very high-risk patients. Some maternal-fetal medicine specialists in the US now routinely prescribe 162 mg (two low-dose aspirin tablets) as a pragmatic compromise between the US and international evidence.
NICE guidance (NG133): The UK's National Institute for Health and Care Excellence recommends 75–150 mg daily from 12 weeks until delivery, reflecting the ASPRE protocol.
FIGO recommendation: The International Federation of Gynecology and Obstetrics recommends aspirin 150 mg nightly based directly on the ASPRE trial protocol.
The bottom line: doses in the 75–162 mg range are all supported by evidence. The critical factors are starting early and taking aspirin consistently.
When to Start and When to Stop Aspirin in Pregnancy
Timing of Initiation
Timing is arguably as important as dose. The biological rationale is straightforward: aspirin must be on board during the window of trophoblast-mediated spiral artery remodeling, which occurs between approximately 8 and 18 weeks of gestation.
- Optimal start: 12–16 weeks of gestation (USPSTF, ACOG, SMFM, NICE, FIGO)
- Acceptable start: Up to 28 weeks per USPSTF, though benefit diminishes significantly after 16 weeks
- Too late: Starting after 20 weeks is unlikely to prevent preeclampsia, as the window for spiral artery remodeling has largely closed
The PARIS meta-analysis demonstrated that aspirin initiated at ≤ 16 weeks reduced preeclampsia by approximately 50%, compared with only about 10% when started later. This finding was reinforced by the Roberge et al. meta-analysis (2017), which showed that aspirin started before 16 weeks and at doses ≥ 100 mg substantially reduced preterm preeclampsia, fetal growth restriction, and perinatal death.
When to Stop
Most guidelines recommend discontinuing aspirin at 36 weeks of gestation. The rationale includes:
- The preventive effect is established earlier in pregnancy; continuing beyond 36 weeks adds little benefit
- Aspirin's antiplatelet effects could theoretically increase bleeding risk during delivery or neuraxial anesthesia (epidural/spinal), though clinical data on this risk are reassuring
- ACOG and SMFM endorse stopping at 36 weeks
Some clinicians continue aspirin until delivery in specific high-risk scenarios (e.g., antiphospholipid syndrome), but this should be an individualized decision.
Bedtime Dosing: What the Evidence Shows
The ASPRE trial specifically instructed participants to take aspirin at bedtime (at night). This was not arbitrary — it was based on chronopharmacology research suggesting that aspirin's antiplatelet and potential blood pressure-lowering effects are enhanced with evening administration due to circadian variation in platelet reactivity and prostanoid synthesis.
A randomized trial by Ayala et al. (2013) in a non-pregnant hypertensive population demonstrated that aspirin taken at bedtime significantly reduced ambulatory blood pressure compared with morning dosing. While direct evidence in pregnant populations is limited to the ASPRE protocol, the theoretical rationale is sound, and bedtime dosing is now recommended by FIGO and considered best practice by many maternal-fetal medicine specialists.
Practical advice for patients:
- Take aspirin at the same time each evening, ideally before bed
- It can be taken with or without food, though a small snack may reduce any gastric discomfort
- If a dose is missed, take it as soon as remembered; do not double the dose
Side Effects, Safety, and Monitoring
Low-dose aspirin in pregnancy has an excellent safety profile. The USPSTF evidence review found no significant increase in placental abruption, postpartum hemorrhage, or fetal intracranial bleeding with doses of 60–150 mg.
Common and Uncommon Side Effects
| Side Effect | Frequency | Clinical Significance |
|---|---|---|
| Mild dyspepsia / heartburn | Common (~5–10%) | Usually manageable; may overlap with pregnancy-related reflux |
| Bruising | Uncommon | Rarely clinically significant at low doses |
| Epistaxis (nosebleeds) | Uncommon | More common in pregnancy regardless of aspirin |
| Postpartum hemorrhage | No significant increase in trials | Reassuring data from meta-analyses |
| Placental abruption | No significant increase in trials | A historical concern not borne out by modern evidence |
| Fetal effects (intracranial hemorrhage, premature ductus arteriosus closure) | Not observed at low doses | Risk is associated with full-dose aspirin (≥ 325 mg), not low-dose |
Monitoring
Routine laboratory monitoring is generally not required for patients taking low-dose aspirin for preeclampsia prevention. Standard prenatal care, including blood pressure measurements and urine protein screening, is sufficient. Platelet counts and coagulation studies are not indicated unless there is a separate clinical reason.
Contraindications and Drug Interactions
Absolute Contraindications
- Aspirin allergy or hypersensitivity (including aspirin-exacerbated respiratory disease)
- Active peptic ulcer disease with bleeding
- Bleeding disorders (severe thrombocytopenia, inherited platelet function defects, hemophilia)
- Third-trimester use of full-dose aspirin (≥ 325 mg) — note this does not apply to low-dose aspirin stopped at 36 weeks
Relative Contraindications and Cautions
- Concurrent anticoagulant therapy (warfarin, heparin) — aspirin may be used concurrently in specific scenarios (e.g., antiphospholipid syndrome with LMWH), but requires specialist oversight
- History of gastrointestinal bleeding
- Severe hepatic impairment
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (high-dose risk; low-dose generally safe)
Drug Interactions of Clinical Relevance
| Interacting Drug | Effect | Management |
|---|---|---|
| NSAIDs (ibuprofen, naproxen) | Competitive COX-1 inhibition may reduce aspirin's antiplatelet effect; NSAIDs generally avoided in pregnancy after 20 weeks | Avoid concurrent use; use acetaminophen for analgesia |
| Heparin / LMWH | Additive bleeding risk | May be co-prescribed in antiphospholipid syndrome under specialist care |
| SSRIs | Additive effect on platelet function | Monitor for bleeding signs; generally safe at low aspirin doses |
| Corticosteroids | Increased GI bleeding risk | Use gastroprotection if both are needed long-term |
| Methotrexate | Aspirin reduces renal clearance of methotrexate | Not relevant in pregnancy (methotrexate contraindicated) |
Special Populations
Individuals with Antiphospholipid Syndrome
Patients with antiphospholipid syndrome (APS) are at markedly elevated risk for preeclampsia, fetal growth restriction, and pregnancy loss. Standard management includes low-dose aspirin plus prophylactic low-molecular-weight heparin throughout pregnancy. In this population, aspirin may be started preconceptionally per ACR/EULAR recommendations, and the combination therapy addresses both thrombotic and placentation-related risks.
Twin and Higher-Order Pregnancies
Multifetal gestation is classified as a high-risk factor, and aspirin is recommended regardless of other risk factors. The ASPRE trial included women with singleton pregnancies only, so the optimal dose for multiples is extrapolated. Most clinicians prescribe 81–162 mg daily.
Chronic Hypertension
Women with pre-existing hypertension are at high risk for superimposed preeclampsia. Aspirin is recommended, and antihypertensive medications (labetalol, nifedipine, methyldopa) should be continued or initiated as indicated. Aspirin does not replace blood pressure management.
Adolescent Pregnancies
Adolescents may have moderate-risk factors (nulliparity) but rarely meet high-risk criteria. Aspirin is prescribed using the same risk-stratification approach. Adherence counseling is particularly important in this group.
Aspirin in Lactation
Low-dose aspirin is considered compatible with breastfeeding per LactMed (NIH). At doses of 81–162 mg, the amount excreted in breast milk is minimal and unlikely to affect the infant. Full-dose aspirin (≥ 325 mg) should be used cautiously due to a theoretical risk of Reye syndrome, though confirmed cases from breast milk exposure have not been reported. Postpartum patients who were taking aspirin for preeclampsia prevention and wish to breastfeed can be reassured.
Red Flags — When to Seek Immediate Medical Attention
Even with aspirin prophylaxis, preeclampsia can still develop. Aspirin reduces risk; it does not eliminate it. Patients should be counseled to seek urgent medical evaluation if they experience any of the following after 20 weeks of gestation:
- Severe headache that does not respond to acetaminophen
- Visual disturbances — blurred vision, flashing lights, scotomata
- Right upper quadrant or epigastric pain — may indicate hepatic involvement (HELLP syndrome)
- Sudden swelling of the face, hands, or feet (beyond normal pregnancy edema)
- Blood pressure readings ≥ 140/90 mmHg on home monitoring
- Decreased fetal movement
- Nausea or vomiting in the second half of pregnancy (not typical morning sickness)
- Shortness of breath or chest tightness
These symptoms may signal preeclampsia, eclampsia, or HELLP syndrome and warrant immediate evaluation, including blood pressure measurement, laboratory assessment (CBC, liver enzymes, creatinine, LDH), and fetal monitoring.
Frequently Asked Questions
Is low-dose aspirin safe throughout pregnancy?
Yes, at doses of 81–162 mg daily, aspirin is considered safe from 12 weeks through 36 weeks of gestation. Large meta-analyses involving tens of thousands of pregnancies have not shown increased risks of major bleeding, placental abruption, or fetal harm. Aspirin is one of the most extensively studied medications in pregnancy.
Can I buy low-dose aspirin over the counter for this purpose?
In many countries, including the United States, 81 mg aspirin is available without a prescription. However, aspirin for preeclampsia prevention should only be taken under the direction of a prenatal care provider who has assessed your individual risk factors. Do not self-prescribe.
What if I don't start aspirin until 20 weeks — is it still worth it?
Starting after 16 weeks provides less benefit than earlier initiation, but the USPSTF states aspirin may be initiated up to 28 weeks if risk factors are identified later. Some reduction in preeclampsia risk may still occur, particularly for term preeclampsia. Discuss with your provider.
Does aspirin prevent preeclampsia completely?
No. Aspirin reduces the risk of preeclampsia — particularly preterm preeclampsia — but does not eliminate it. Even with optimal prophylaxis, some women will develop preeclampsia. Continued prenatal surveillance is essential.
Should I take enteric-coated or regular aspirin?
Either formulation is acceptable. Enteric-coated aspirin may cause less gastric irritation, though at low doses this is rarely a significant issue. Some pharmacokinetic data suggest uncoated aspirin has faster absorption, but no clinical trial has demonstrated a difference in preeclampsia outcomes by formulation.
Can aspirin be combined with calcium supplementation?
Yes. The WHO recommends calcium supplementation (1.5–2 g/day) in populations with low dietary calcium intake to reduce preeclampsia risk, and this can be used alongside low-dose aspirin. These interventions work through different mechanisms and are not mutually exclusive.
Will taking aspirin affect my delivery or epidural?
At low doses discontinued at 36 weeks, aspirin does not significantly affect epidural or spinal anesthesia safety. Most anesthesia guidelines do not consider low-dose aspirin a contraindication to neuraxial procedures. If aspirin is continued closer to delivery, discuss timing with your obstetric anesthesiologist.
I had preeclampsia in my last pregnancy. Should I definitely take aspirin this time?
A prior history of preeclampsia is a high-risk factor, and aspirin prophylaxis is recommended in subsequent pregnancies by USPSTF, ACOG, and SMFM. Ideally, discuss this with your provider before or early in pregnancy so aspirin can be started by 12–16 weeks.
References
-
U.S. Preventive Services Task Force. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Recommendation Statement. JAMA. 2021;326(12):1186–1191. USPSTF Recommendation
-
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613–622. PMID: 28657417
-
Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;326(12):1192–1206. PMID: 34581729
-
Roberge S, Bujold E, Nicolaides KH. Aspirin for the Prevention of Preterm and Term Preeclampsia: Systematic Review and Meta-Analysis. Am J Obstet Gynecol. 2018;218(3):287–293.e1. PMID: 29138036
-
Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet Agents for Prevention of Pre-eclampsia: A Meta-Analysis of Individual Patient Data. Lancet. 2007;369(9575):1791–1798. PMID: 17512048
-
Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet Agents for Preventing Pre-eclampsia and Its Complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659. PMID: 31684684
-
ACOG. Gestational Hypertension and Preeclampsia. Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237–e260. ACOG Practice Bulletin
-
NICE. Hypertension in Pregnancy: Diagnosis and Management. Guideline NG133. 2019 (updated 2023). nice.org.uk/guidance/ng133
-
Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on Pre-eclampsia: A Pragmatic Guide for First-Trimester Screening and Prevention. Int J Gynecol Obstet. 2019;145(Suppl 1):1–33. PMID: 30817987
-
LactMed. Aspirin. In: Drugs and Lactation Database. National Library of Medicine. ncbi.nlm.nih.gov/books/NBK500986
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in medication safety, evidence-based therapeutics, and patient education. He contributes to PillsCard.com as a medical writer and reviewer, translating complex pharmaceutical evidence into accessible, clinically accurate content for patients and healthcare professionals worldwide. His work emphasizes guideline-driven recommendations, transparent sourcing, and a commitment to pharmacovigilance.
Medical Disclaimer
This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects published clinical guidelines and peer-reviewed evidence available at the time of writing but should not replace individualized evaluation by a qualified healthcare provider. Pregnancy management decisions — including the use of aspirin for preeclampsia prevention — must be made in consultation with your obstetrician, midwife, or maternal-fetal medicine specialist based on your specific medical history and risk factors. Always seek the advice of your healthcare provider with any questions regarding a medical condition or medication. Do not start, stop, or change any medication without professional guidance. PillsCard.com and its contributors assume no liability for actions taken based on the content of this article.